Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8528143 | 0.95 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL22996211 | 0.91 | CA1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL27741035 | 0.87 | CA2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL100146 | 0.87 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL1569661 | 0.87 | CA2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL24667825 | 0.87 | NAMPT (0.56) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL11961188 | 0.86 | CA2 (0.55) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL1065312 | 0.86 | CA2 (0.55) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL23449213 | 0.86 | CA2 (0.58) | MAPTTDP1CA2CA1NAMPT | |
| SCHEMBL21521028 | 0.86 | CA2 (0.55) | NPC1RAB9ASMN1; SMN2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115722266-A | Novel aza-carbene-amido-ruthenium catalyst and preparation method and application thereof | 广东药科大学 | 2023-03-03 | — | — | CN | disclosed |
| WO-2021106979-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021041770-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010053182-A1 | KYNURENINE PRODUCTION INHIBITOR | 協和発酵キリン株式会社 (JP) | 2010-05-14 | — | — | WO | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| CN-1293057-C | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| CN-1438993-A | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | NPC1 321/4885RAB9A 3031/4885SMN1; SMN2 3965/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | NPC1 358/4885RAB9A 3387/4885SMN1; SMN2 3817/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | NPC1 4522/4885RAB9A 3666/4885SMN1; SMN2 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.